gliclazide has been researched along with Cirrhosis in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 2 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Cai, C; Guo, J; Jiang, Y; Li, J; Luo, Y; Rong, R; Zhang, P; Zhang, Y; Zhu, T | 1 |
| Li, B; Shen, T; Tang, W; Xie, Y; Zhang, J; Zhang, X; Zhang, XL; Zhu, J | 1 |
2 other study(ies) available for gliclazide and Cirrhosis
| Article | Year |
|---|---|
Transcriptional profile changes after treatment of ischemia reperfusion injury-induced kidney fibrosis with 18β-glycyrrhetinic acid.
Topics: Animals; Fibrosis; Glycyrrhetinic Acid; Kidney; Mice; Renal Insufficiency, Chronic; Reperfusion Injury | 2022 |
18β-Glycyrrhetinic acid monoglucuronide (GAMG) alleviates single-walled carbon nanotubes (SWCNT)-induced lung inflammation and fibrosis in mice through PI3K/AKT/NF-κB signaling pathway.
Topics: Animals; Collagen; Fibrosis; Glycyrrhetinic Acid; Lung; Mice; Nanotubes, Carbon; NF-kappa B; Phosphatidylinositol 3-Kinases; Pneumonia; Proto-Oncogene Proteins c-akt; Pulmonary Fibrosis; Signal Transduction | 2022 |